Patents Assigned to Bristol-Myers
  • Bicyclo[2.2.2]acid GPR120 modulators
    Patent number: 9598390
    Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Hao Zhang, Peter T. W. Cheng, Shiwei Tao
  • Hepatitis C virus inhibitors
    Patent number: 9598433
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Eric P. Gillis, Eric Mull, Michael S. Bowsher, Qian Zhao, Paul Michael Scola
  • Crystalline form of -dicyclopropyl-4-(1,5-dimethyl-1-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
    Patent number: 9598413
    Abstract: Crystalline form, Form T2H1.5-4, of N,Ndicyclopropyl-4-(1,5-dimethyl-1 Hpyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide, (Compound (I)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising Form T2H1.5-4 of Compound (I) as well as a method of using the Form T2H1.5-4 of Compound (I) in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: March 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventor: Shella Tameze
  • Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors
    Patent number: 9598423
    Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: March 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Peiying Liu, Mark D. Wittman, Bradley C. Pearce, Erika M. V. Araujo, Bireshwar Dasgupta, Jalathi Surendran Nair, Sakthi Kumaran Janakiraman, Chandrasekhar Reddy Rachamreddy, Mallikarjuna Rao Mettu, Arul Mozhi Selvan Subbiah Karuppiah, Bandreddy Subba Reddy, Pulicharla Nagalakshmi, Rajesh Onkardas Bora, Shilpa Holehatti Maheshwarappa, Selvakumar Kumaravel, Dibakar Mullick, Ramesh Sistla
  • Substituted bicyclic heteroaryl compounds
    Patent number: 9598436
    Abstract: Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: March 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Audris Huang
  • Sensitive method to analyse free PEG-maleimide
    Patent number: 9594025
    Abstract: The present invention relates generally to a novel method using HPLC and fluorescence detection of free PEG-mal in PEGylated proteins and PEG-mal raw materials by adding a fluorescent label to the free PEG-mal.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: March 14, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mei Lin, Anulfo Valdez
  • Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
    Patent number: 9593117
    Abstract: Crystalline form, Form HI.5-4, of N,N-di-cyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide, (Compound I) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising Form HI.5-4 of Compound I as well as a method of using the Form HI.5-4 of Compound I in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: March 14, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventor: Shella Tameze
  • Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
    Patent number: 9593116
    Abstract: Crystalline form, Form T1H1.5-4, of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl -1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (Compound (I)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising Form T1H1.5-4 of Compound (I) as well as a method of using the Form T1H1.5-4 of Compound for the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: March 14, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashok Vinayak Purandare, Honghe Wan
  • Imide and acylurea derivatives as modulators of the glucocorticoid receptor
    Patent number: 9593113
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-KB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: March 14, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Weinstein, Hua Gong, Michael G Yang, Zili Xiao
  • Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
    Patent number: 9586900
    Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: March 7, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Saleem Ahmad, Guohua Zhao, William N. Washburn
  • MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES
    Publication number: 20170057961
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: January 30, 2015
    Publication date: March 2, 2017
    Applicant: Bristol-Myers Squibb Company
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • Hepatitis C virus inhibitors
    Patent number: 9580463
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: February 28, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pulicharla Nagalakshmi, Kandhasamy Sarkunam, Kishore V. Renduchintala, Paul Michael Scola
  • Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
    Patent number: 9580422
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein R* is an isotopically labeled hydroxypropyl moiety.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: February 28, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yaofeng Cheng, Weiqi Chen, Brad D. Maxwell, Bach D. Tran, Jun Li
  • METHODS OF TREATING TRANSPLANT REJECTION USING A DOMAIN ANTIBODY DIRECTED AGAINST CD40
    Publication number: 20170051059
    Abstract: Methods of treating renal transplant rejection using anti-CD40L domain antibodies are provided. The anti-CD40L dAbs are less likely to cause platelet aggregation and thus cause thromboembolism. Appropriate anti-CD40L dAbs doses and administration regimens are also provided. Combination treatments for transplant rejection, particularly renal transplant rejection, using anti-CD40L dAbs, a CTLA4 mutant molecule (e.g., belatacept) and/or anti-CD28 optionally with conventional immunosuppressive renal transplant therapy are provided.
    Type: Application
    Filed: March 19, 2015
    Publication date: February 23, 2017
    Applicants: Bristol-Myers Squibb Company, Bristol-Myers Squibb Company
    Inventors: Anish SURI, Steven G. NADLER, Christian P. LARSEN, Andrew Briane ADAMS
  • METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20170037132
    Abstract: This disclosure provides a method for treating HPV-positive squamous cell carcinoma of the head and neck comprising administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The disclosure also provides a method for treating HPV-negative squamous cell carcinoma of the head and neck administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The subject can be additionally administered another anti-cancer agent.
    Type: Application
    Filed: July 14, 2016
    Publication date: February 9, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Demetrios MANEKAS, Joseph Grosso, Jeffrey Anderson
  • Hepatitis C virus inhibitors
    Patent number: 9561212
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: February 7, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey Lee Romine, Zhong Yang, Gan Wang, Van N. Nguyen, John A. Bender, Denis R. St. Laurent, Makonen Belema
  • Fibronectin based scaffold proteins having improved stability
    Patent number: 9562089
    Abstract: The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: February 7, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, John O'Loughlin, Bernice Yeung, Yihong Zhang
  • Polycyclic LPA1 antagonist and uses thereof
    Patent number: 9556133
    Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: January 31, 2017
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, AMIRA PHARMACEUTICALS, INC.
    Inventors: Jason Edward Brittain, Thomas Jon Seiders, Christopher David King, Victor W. Rosso
  • Compound for the treatment of hepatitis C
    Patent number: 9556162
    Abstract: The present invention provides (R)-5-(3-((2-(1,2,4-oxadiazol-3-yl)propan-2-yl)carbamoyl)phenyl)-6-(sec-butyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (formula I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compound. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: January 31, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Katharine A. Grant-Young
  • Methods and intermediates for the preparation of (4bS,5aR)-12-cyclohexyl-N-(N,N-dimethylsulfamoyl)-3-methoxy-5a-((1R,5S)-3-methyl-3,8-diazabicyclo [3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-A]indole-9-carboxamide
    Patent number: 9556204
    Abstract: The present invention provides methods and intermediates for the preparation of (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide (formula I), including pharmaceutically acceptable salts. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: January 31, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Albert J. DelMonte, Kenneth J. Natalie, Jr., Kenneth J. Fraunhoffer, Christina Ann Risatti, Chao Hang, Zhinong Gao, Akin H. Davulcu, Wenhao Hu